Galenica holds the cleaner structural position, with the lead spread across growth and stability. CVS Health still has the edge on growth, which keeps the comparison from looking entirely one-sided. In the market, CVS Health carries the stronger setup — intact trend against Galenica's broken trend. That leaves a split case: the structural lead stays with Galenica, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (CVS: Russell 1000, GALE.SW: STOXX 600).
The page question resolves through growth, where CVS Health Corporation holds the stronger read even though the broader score still favours Galenica AG.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
The strongest overlap appears in capital structure and margin consistency.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Structure stays fairly close here, while current pricing still looks more supportive for Galenica AG.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where CVS and GALE.SW each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The clearest distance comes from a stronger growth profile.
On the market side, CVS Health carries the stronger trend while Galenica's trend has broken — the market setup does not confirm the structural advantage.
The lead is built on both growth and stability — though growth still provides a counterweight.
Break down the CVS vs GALE.SW comparison across all dimensions with the full interactive tool.
Explore how CVS and GALE.SW each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.